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3Abstract
Acute-on-Chronic Liver Failure (ACLF) in cirrhosis is characterized by acute
decompensation (AD), organ failure(s) and high short-term mortality. Recently, we
have proposed [Systemic Inflammation (SI) Hypothesis] that ACLF is the expression
of an acute exacerbation of the SI already present in decompensated cirrhosis. This
study was aimed at testing this hypothesis and included 522 patients with
decompensated cirrhosis (237 with ACLF) and 40 healthy subjects. SI was assessed
by measuring 29 cytokines and the redox state of circulating albumin (HNA2), a
marker of systemic oxidative stress. Systemic circulatory dysfunction (SCD) was
estimated by plasma renin (PRC) and copeptin (PCC) concentrations. Measurements
were performed at enrolment (baseline) in all patients and sequentially during
hospitalization in 255. The main findings of this study were: (1) Patients with AD
without ACLF showed very high baseline levels of inflammatory cytokines, HNA2,
PRC and PCC. Patients with ACLF showed significantly higher levels of these
markers than patients without ACLF; (2) Different cytokine profiles were identified
according to the type of ACLF precipitating event (active alcoholism/acute alcoholic
hepatitis, bacterial infection, others); (3) Severity of SI and frequency and severity of
ACLF at enrolment were strongly associated. The course of SI and the course of
ACLF (improvement, no change or worsening) during hospitalization and short-term
mortality were also strongly associated; (4) The strength of association of ACLF with
SI was higher than with SCD. Conclusion: Our data support SI as the primary driver
of ACLF in cirrhosis.
4Acute-on-Chronic Liver Failure (ACLF) in cirrhosis is a highly prevalent syndrome
characterized by acute decompensation (AD), organ/system failure(s) and high 28-
day mortality (32%) (1). ACLF is classified in 3 grades of severity (ACLF-I, II and III)
according to the number of organ failures and may follow four different clinical
courses during hospitalization: resolution, improvement (reduction in ACLF-grade),
steady course, or worsening (2).
The Systemic Inflammation (SI) Hypothesis (3) proposes that ACLF is due to
aggravation of the SI and associated systemic circulatory dysfunction (SCD) already
present in AD, which leads to organ failure(s) as a consequence of organ hypo-
perfusion and direct deleterious effects of inflammatory mediators on the organ
microcirculation and cell physiology homeostasis. According with this hypothesis, AD
would occurs in the setting of chronic SI due to translocation of pro-inflammatory
molecules (Pathogen Associated Molecular Patterns, PAMPs) from the intestinal
lumen to the systemic circulation and/or to the release or Damage Associated
Molecular Patterns (DAMPs) from the diseased liver. ACLF would be the result of
further increase of SI in the context of precipitating events [PE: mainly active
alcoholism/Acute alcoholic hepatitis (AAH), bacterial infections, or other PE]. The SI
Hypothesis was based on cytokine studies in small series of patients (4-7) and on the
CANONIC study, in which a close relationship between blood leukocytes (WBC) and
C-reactive protein (CRP) levels and the presence and severity of ACLF was
observed (1).
In the current study we assessed the SI Hypothesis by two approaches. The first was
aimed at examining the relationship between markers of SI, measured at enrolment
and sequentially during hospitalization, and the presence, severity and clinical course
5of ACLF and associated mortality in 552 patients hospitalized for AD. The second
approach was aimed at assessing whether, as proposed by the SI hypothesis, ACLF
in cirrhosis is not only due to an accentuation of the SCD and organ hypo-perfusion
related to SI, but also to direct deleterious effects of SI in organ function. This
assessment was performed by assessing the strength of the association of SCD and
SI with ACLF and mortality.
Experimental Procedures
Patient selection, blood sampling, data collection and diagnostic criteria of
organ failure and ACLF.
Two-hundred-thirty-seven patients with ACLF, either present at enrolment (n=180) or
developed during hospitalization (n=57), and 285 patients without ACLF derived from
the CANONIC investigation (1) were studied. Selection criteria were: 1. Availability of
blood samples at enrollment; 2. Prospective intensive surveillance during
hospitalization. Follow-up plasma samples obtained at pre-specified visits during
hospitalization (2, 3-7, 8-14, 15-21 and 22-28 days after enrolment) were available in
255 patients, 157 with ACLF. Sequential blood samples prior to ACLF, at ACLF
diagnosis and during post-ACLF follow-up were available in 20 out of the 57 patients
developing ACLF during hospitalization. In the remaining patients with ACLF there
were only samples at ACLF diagnosis and during follow-up. Samples were obtained
in 2011 in Vacutainer EDTA tubes, centrifuged at 4ºC and the plasma frozen at -
90ºC. Measurements were performed during 2015.
Clinical, laboratory and follow-up data were obtained from individual electronic-CRF.
There was no patient with HIV infection. Diagnosis of organ failure, ACLF and ACLF
grades are based on the CLIF-Consortium Organ Failure score and the Canonic
6study criteria (1,8) (see Supporting Information). Clinical diagnosis of AAH was
based on the NIAAA Alcoholic Hepatitis Consortia criteria (9): active alcoholism,
serum bilirubin>3 mg/dL, AST>50 IU/mL and AST/ALT ratio> 1.5. SIRS was
diagnosed using WBC count, heart and respiratory rates and body temperature (10).
Characterization of SI in AD. Relationship with ACLF.
To characterize SI, we measured the plasma levels of 29 cytokines involved in innate
and adaptive immune responses and the redox state of circulating albumin (a marker
of systemic oxidative stress (11,12)). Baseline measurements were obtained at
enrolment or at ACLF onset in the 20 out of the 57 patients developing ACLF during
hospitalization. To assess the role of SI in the pathogenesis of ACLF, we compared
baseline plasma cytokine levels of patients with and without ACLF at enrolment and
examined the relationship between these measurements and ACLF severity. Also we
assessed the chronological relationship between changes in SI and the course of
ACLF during hospitalization by comparing the levels of SI markers at ACLF diagnosis
with those at the last measurement during hospitalization (prior to discharge or liver
transplantation or death). Median time from enrolment to last assessment: 15 days;
percentile 25-75:7-28). Differences in baseline cytokine profiles according to the
etiology (PE) were also assessed to identify potential differences in SI mechanisms.
Finally, pro-inflammatory/anti-inflammatory cytokine ratios were determined in
healthy subjects and patients with and without ACLF to assess the profile of pro- and
anti-inflammatory cytokine response in these patients. Cytokines were measured
using a multiplexed bead-based immunoassay on a Luminex 100 Bioanalyzer
(Supporting Information and Supplementary Table 1).
Systemic oxidative stress was estimated by measuring the percentage of albumin
oxidized at the Cysteine-34 residue (Cys34) over the total albumin concentration.
7The free Cys34 accounts for about 80% of the antioxidant capacity of human plasma
(12,13). In the presence of systemic oxidative stress, Cys34 is converted from the
reduced form with Cys34 into the free sulphydryl form (human mercaptalbumin,
HMA) to mixed disulfides (human nonmercaptalbumin 1, HNA1). This process is
reversible (14-16). A smaller fraction of Cys34, however, is highly oxidized to
sulfenic, sulfinic and finally sulfonic forms (human nonmercaptalbumin 2, HNA2).
Oxidation of albumin to HNA2 is irreversible and causes intense modifications of the
protein structure (15,16). HNA1+HNA2 as well as HNA2 were used as markers of
systemic oxidative stress(17-19). Reasons for the selection of the redox state of
albumin over other markers of systemic oxidative stress and the methodology of
measurement are detailed in Supporting Information.
Strength of the association of markers of SI and of SCD with ACLF or ACLF
with renal failure (ACLF-RF).
Systemic circulatory function defines a series of physiological processes influencing
the cardiac output and the activity of endogenous vasoactive systems that regulate
arterial pressure and global organ perfusion. Micro-circulatory function (which is
mainly dependent of endothelial and tissue factors) regulates the blood and oxygen
delivery to the cells. Since plasma renin concentration (PRC) and the plasma
concentration of copeptin (PCC) are very sensitive to changes in effective circulating
blood volume (20,21), they were selected as markers of systemic circulatory
dysfunction for this study. Copeptin is a stable cleavage product of the C-terminal
part of the antidiuretic hormone (ADH) precursor that is produced in a 1:1 fashion
with ADH. It is widely used to estimate vasopressin release because it allows an
easier and more accurate immunological testing than ADH (21). Other criteria used
for the selection of PRC and PCC as markers of systemic circulatory dysfunction and
8the methodology of measurements are detailed in Supporting Information.
Copeptin (as ADH) is filtered by the glomeruli and therefore may overestimate ADH
secretion in patients with ACLF-RF.
The strength of the association of ACLF with PRC and with IL-8, IL-6 or HNA2 was
estimated to assess whether ACLF is related not only to SCD but also to other
effects of SI in organ function. IL-8, IL-6 and HNA2 were selected because they were
the inflammatory markers more strongly associated with ACLF in our patients (see
Results). PRC was selected because it was not influenced, as copeptin, by GFR in
our patients (see Results) The strength of the association of ACLF-RF with markers
of SI and PRC were also compared as an outcome, since renal failure is a
paradigmatic organ failure in cirrhosis thought to be caused by severe impairment in
cardiovascular function and organ hypo-perfusion (3,20,22). Four different
approaches to analysis were used.
First, we visually assessed the distribution of baseline IL-8, IL-6, HNA2, and PRC
according to the presence of ACLF and ACLF-RF by means of a scatter-plot of
patients’ values. The strength of association between SI or SCD and ACLF or ACLF-
RF was estimated by comparing (Chi-square tests) the progression of ACLF or
ACLF-RF frequency at three different levels (tertiles) of each SI markers versus PRC.
Second, we assessed the percentage of patients with ACLF or ACLF-RF showing
normal levels of IL-8, IL-6, HNA2 and PRC.
The third approach included two different analyses: 1. A logistic regression model to
assess which markers (IL-8, IL-6, HNA2 and/or PRC) were independently associated
with the presence of ACLF or ACLF-RF; 2. A linear regression model assessing the
9correlation of IL-8, IL-6, HNA2 and PRC with CLIF-Consortium Organ Failure score
and serum creatinine as markers of ACLF and renal impairment severity.
Finally we assessed the association of changes in markers of SI and PRC during
hospitalization with changes in the clinical course of patients with and without ACLF.
SI, SCD and mortality.
We also assessed the strength of the association of baseline levels of SI and SCD
markers and of changes in these markers during hospitalization with short-term (28-
day and 90-day) mortality.
Data analysis and statistical details
Among the 29 cytokines determined, 12 were undetectable in a high percentage
(more than 30%) of the cirrhotic patients studied (Supplementary Table 2). Due to
this feature, two independent analyses on the association of cytokines with ACLF
and mortality were performed. The main analysis, which included the 17 cytokines
showing detectable plasma levels in most patients, is detailed in the main body of the
article. Undetectable levels of healthy subjects in this analysis (the majority of values
for some cytokines) were assigned a value equal to the lower limit of detection. The
second analysis was performed with the 12 cytokines with more than 30% of
undetectable values. Results with this group are briefly mentioned in the text of the
article and detailed in the Supporting Information.
Discrete variables are shown as counts (percentage) and continuous variables as
mean (standard deviation). Non-normally distributed variables are summarized by the
median (interquartile range) and were log-transformed for some statistical analyses
and for graphical comparisons. In univariate statistical comparisons, the Chi-square
test was used for categorical variables, while the Student’s t-test or ANOVA were
used for normal continuous variables and the Wilcoxon signed rank test or the
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Kruskall-Wallis test for continuous variables not normally distributed. In all statistical
analyses, significance was set at p<0.05.
Results
Characterization of SI in patients with AD. Relationship with ACLF.
The patient characteristics were similar to those of the whole CANONIC cohort (1)
(Supplementary Table 3). Active alcoholism and bacterial infections were the most
frequent PEs of ACLF, although in approximately 40% of patients no PE was
identified. The presence and severity of ACLF and prognosis correlated closely with
WBC and CRP levels. The prevalence of AAH (47 patients) among the 522 patients
studied was only of 9% (65% among the 72 patients with active alcoholism). AAH
was significantly more frequent in patients with ACLF (12.2%) than in those without
ACLF (6.3%) (p<0.05). Only 78 patients (14.9%) showed SIRS. SIRS was
significantly more frequent (p<0.05) in patients with bacterial infection (23.6% vs
11.9%), AAH (25.5% vs 13.9%) or ACLF (19.9% vs 10.9%).
Tables 1 and 2 show the results obtained with the 17 cytokines with detectable
values in more than 70% of the patients. They were categorized as either cytokines
with predominant inflammatory properties (TNF, IL-6, IL-8, MCP-1, IP-10, MIP-1
G-CSF and GM-CSF) in the innate immune system; cytokines with predominant anti-
inflammatory properties (IL-10 and IL-1ra) or cytokines with other actions including
cytokines with predominant activity in the adaptive immune system (IFN, IFN2, IL-
17a and IL-7), cytokines with predominant chemotactic activity on eosinophils
(eotaxin) and cytokines that function as growth factors (EGF and VEGF)
(Supplementary Table 4).
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As compared to healthy controls, patients with cirrhosis showed markedly increased
levels of all cytokines (Table 1). Patients presenting ACLF exhibited significantly
higher levels of pro-inflammatory cytokines than patients without ACLF. The anti-
inflammatory cytokines IL-10 and IL-1ra followed a similar pattern. In contrast,
differences in the plasma levels of the remaining cytokines were slight or not
significant. No significant differences in plasma cytokine levels at ACLF diagnosis
were observed between patients with ACLF at enrolment and those who developed
ACLF after enrolment (data not shown).
There was a clear direct relationship between the intensity of SI and severity of ACLF
as indicated by a parallel and significant increase in IL-6, IL-8 and IL-1ra from ACLF
grade I to ACLF grades II and III (Table 2).
The IL-8/IL-10 and IL-6/IL-10 ratios were determined as markers of the pro-
inflammatory/anti-inflammatory cytokine response (Supplementary Figure 1). The
two ratios were significantly higher in patients with cirrhosis than in healthy subjects.
No significant differences between patients with and without ACLF were observed.
Supplementary Tables 5 and 6 show the results obtained with the cytokines
showing detectable values in less than 70% of patients. All cytokines included in this
analysis were also significantly higher in patients with decompensated cirrhosis with
and without ACLF than in healthy controls (Supplementary Table 5). However,
significant differences between patients with and without ACLF were observed only in
the inflammatory cytokine MIP-1α (higher in patients with ACLF). There were no 
significant differences in any of the cytokines included in this analysis across the
three grades of severity of ACLF (Supplementary Table 6).
The profile of the 17 cytokines included in the main analysis varied according to the
PE in patients with ACLF (Table 3). ACLF precipitated by bacterial infection showed
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higher levels of TNFα, IL-6 and IL-1ra than ACLF precipitated by active alcoholism 
(p=0.004; p=0.02; and p=0.0269, respectively) or ACLF associated with other PEs or
without PE (p=0.04; p=0.0002; and p=0.02, respectively). ACLF precipitated by active
alcoholism showed higher levels of IL-8 than ACLF precipitated by bacterial infection
(p=0.0001) or ACLF associated with other PEs or without PE (p=0.001). The cytokine
profile in ACLF precipitated by both bacterial infections and active alcoholism shared
the characteristics of ACLF precipitated by infection and active alcoholism alone. In
ACLF patients with other PEs or without PE no cytokine showed significantly
increased levels in comparison to the other groups of patients with ACLF.
Supplementary Table 7 shows that the profile associated with active alcoholism was
due to a great extent to the extremely high values of IL-8 observed in patients with
AAH. However, the plasma levels of IL-8 were also higher in patients with active
alcoholism without AAH than in those without active alcoholism (Supplementary
Table 7). This increase in the plasma levels of IL-8 observed in patients with
alcoholic cirrhosis, active alcoholism but no AAH was not detected in alcoholic
cirrhotic patients who stopped drinking (Supplementary Table 7).
Supplementary Table 8 shows the cytokine profile in patients with and without
SIRS. Patients with SIRS showed significantly higher plasma levels of the pro-
inflammatory cytokines IL-6, IL-8, MCP-1, MIP-1β and G-CSF and of the anti-
inflammatory cytokines IL-10 and IL-1ra than patients without SIRS.
HNA1+HNA2 and HNA2 were markedly increased (p<0.001) in cirrhotic patients with
and without ACLF as compared to healthy controls (Table 1). Values for both
HNA1+HNA2 and HNA2 were significantly higher in patients with ACLF than in those
without (Table 1). There were no significant changes in the redox state of albumin
across the three ACLF grades (Table 2).
13
SCD in patients with and without ACLF.
As shown in Table 1, PRC and PCC were markedly above normal range in patients
with and without ACLF but values of these markers were significantly higher in the
former than in the latter group. PCC was significantly higher in patients with ACLF-RF
[48.7 (19.8-81.1)] than in patients with ACLF without renal failure [25.1(10.2-44.8)
pmol/L; p<0.001]. In contrast, no significant differences in PRC were observed
between these two groups [112 (35-276) vs 179 (33-460) microIU/ml; p=0.285].
These results indicate that PCC is a poor marker of SCD in patients with ACLF-RF
since it reflects not only an increased release of the ADH precursor by the
neurohypophysis as a consequence of SCD but also an impaired renal clearance of
copeptin. PCC values in patients with ACLF without renal failure were significantly
higher than those observed in the group of patients without ACLF [25.1(10.2-44.8 vs
9 (3-23) pmol/L; p<0.001)] indicating that ADH secretion is markedly increased in
ACLF. No significant changes in PRC and PCC were observed across the three
ACLF grades (Table 2).
Strength of the association of markers of SI and of SCD with the frequency and
severity of ACLF or ACLF-RF at enrolment and the course of ACLF during
hospitalization.
IL-8, IL-6 and HNA2, the SI markers more closely associated with the presence and
severity of ACLF at enrolment (Tables 1 and 2), and PRC were analyzed for this
purpose. PCC was not included in this analysis due to its low ability for the
assessment of SCD in patients with ACLF-RF.
Figure 1 shows the distribution of patients with (red dots) and without (green dots)
ACLF according to baseline values of PRC and IL-8 (left) or HNA2 (right) in the whole
series. Patients with ACLF were predominantly distributed in the right part of the
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figures (higher degree of SI, upper panels) and the strength of association of ACLF
with both SI markers was greater than that with PRC (lower panels). Similar pattern
of distribution was obtained with IL-6 (Supplementary Figure 2), with IL-8, IL-6 (not
shown) and HNA2 after excluding patients with active alcoholism (Supplementary
Figure 3) or with IL-8, IL-6 (not shown) and HNA2 when only patients with ACLF-RF
were considered (Supplementary Figure 4).
Among the patients with ACLF, only 2 (1.7%) showed normal values (below the 95th
percentile of the distribution in healthy subjects) of IL-6 and none had normal values
of IL-8. In contrast, 17.7% showed normal PRC values (p<0.001) and 8.0%
presented normal HNA2 values (p<0.001) (Figure 2A). The corresponding
percentages in relation to patients with ACLF-RF were 0%, 0.8%, 16.4% and 8%,
respectively (p<0.001) (Figure 2B). The corresponding values after excluding
patients with active alcoholism are represented in Supplementary Figure 5.
The logistic regression model showed that the presence of ACLF was independently
associated with IL-6, IL-8 and HNA2 but not with PRC (log PRC: RR 1.05, CI: 0.94-
1.16, p=0.413; log IL-8: RR: 1.73, CI: 1.40-2.14, p<0.001; log IL-6: RR: 1.33, CI:
1.12-1.57, p<0.001; log HNA2: RR: 2.78, CI: 2.07-3.71, p<0.001). Only IL-8 and
HNA2 were found to be significantly associated with the presence of ACLF-RF (RR:
1.45, 95%CI: 1.17-1.80, p<0.00 and RR: 2.80, 95%CI: 1.98-3.95, p<0.001,
respectively).
The stepwise linear regression model fitted for CLIF-C Organ Failure Score based on
the significance of the increase in model R-Square allowed to select HNA2
(p<0.0001) and both cytokines (IL-8, p<0.0001; IL-6, p=0.0008) as the markers most
strongly related to the severity of ACLF. Similarly the stepwise model fitted for serum
creatinine allowed to select HNA2 (p<0.0001) and IL-6 (p=0.0114) as the markers
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more strongly related to the severity of renal failure. In both models, PRC did not
contribute significantly to improve the final R-Square.
There was a significant association between changes in markers of SI during
hospitalization and the course of ACLF (Table 4). Improvement of ACLF was
associated with decrease whereas worsening of ACLF was associated with increase
in IL-6, IL-8 and HNA2. Inflammatory markers did not change in the steady form of
ACLF or in patients with no ACLF throughout the study. In contrast, no relationship
was observed between changes in PRC and the clinical course of ACLF
SI and mortality.
The strength of association between SI, SCD and short-term mortality were also
assessed considering IL-8, IL-6, HNA2 and PRC values. Baseline values of IL-8, IL-6
(not shown) and HNA2 but not of PRC were strongly associated with 28-day mortality
(Figure 3) and 90-day mortality (Supplementary Figure 6). Similarly, there was a
significant association between the course of SI during hospitalization and the 28-day
and 90-day mortality (Table 5). One hundred and three patients had CRP data
available at enrolment and at the last follow-up assessment. Changes in CRP from
enrolment in those patients who survived at 28 (median -4.0, IQR -13.1-1.6) and 90
days (-2.4, -11.1-1.9) were not significantly different from those corresponding to
patients who died (-1.3, -19.6-3.7 and -7.1, -20.7-0; p-values 0.4918 and 0.2044,
respectively). Twenty-eight-day and 90-day mortality rates were also significantly
associated (p<0.0001) with SIRS at enrolment (23 out of 78 patients with SIRS,
29.5%, and 47 out of 433 without SIRS, 10.6%, died within 28-day after enrolment; at
90 days; the mortality rates were 42.9% and 21.6%, respectively).
Eighteen patients showed extremely high levels of IL-8 (>800 UI/ml) and/or IL-6
(>1000 UI/ml) at enrolment (Figure 2). The prevalence of severe forms of ACLF
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(grades 2 or 3) and the 28-day mortality rate in this group of patients (39% and
28%%, respectively) was higher (p= 0.0833 and p=0.0774) than in the rest of the
patients (21% and 13%, respectively).
Discussion
The discussion of the article is divided in four parts: 1. Role of SI in the pathogenesis
and clinical course of AD and ACLF; 2. Cytokine response; 3. Mechanisms of organ
failure in ACLF; 4. Relationship between SI and mortality.
The first part of the analysis (Tables 1-3) strongly suggests that SI is a major
mechanism of AD and ACLF and supports most of the proposals of the SI
Hypothesis: 1. AD of cirrhosis occurs in the setting of severe SI and oxidative stress;
2. SI is significantly more severe in patients with ACLF than in patients without ACLF.
Interestingly, the reported levels of IL-6, IL-8 and TNFα in patients with severe 
sepsis, a condition also associated with organ failure, are similar to those found in
our patients with ACLF (23-25); 3. Severity of SI correlates closely with severity of
ACLF; 4. Finally, the course of SI during hospitalization is strongly associated with
the course of AD and ACLF (development of ACLF during hospitalization in patients
without ACLF at enrolment or improvement, steady course or worsening of ACLF in
patients with ACLF at enrolment).
The characterization of cytokine response in our patients (second part of the
analysis; Tables 1-3, Supplementary Table 7 and Supplementary Figure 1) disclosed
interesting features. Whereas all the 17 cytokines and chemokines included in the
main analysis were significantly increased in patients with AD with respect to healthy
controls, only those involved in innate immune response were clearly ‘upregulated’ in
patients with ACLF with respect to patients without ACLF. Indeed, we found that
patients with ACLF had a predominance of pro-inflammatory cytokines (i.e., TNFα 
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and IL-6) and chemokines (IL-8, MCP-1, IP-10 and MIP-1β). These patients also had 
increased levels of G-CSF and GM-CSF, key regulatory cytokines that target
committed progenitors to promote differentiation and activation of monocytes and
neutrophils (26). In contrast, among other cytokines that are involved in the activation
and shaping of the adaptive immune system (IFNγ, IL-17a and IL-7), IFNγ was only 
slightly higher in patients with ACLF than in those without. These findings suggest
that whereas activation of both the innate and adaptive immune systems participates
in the SI associated with AD, a dysregulated innate immune response might be the
predominant mechanism in the progression of AD to ACLF.
The assessment of the overall cytokine profile showed that not only pro-inflammatory
molecules but also major anti-inflammatory cytokines such as IL-10 and IL-1ra were
increased in patients with AD with and without ACLF indicating a generalized
activation of the inflammatory cytokines. There was, however, a clear unbalance in
favor of pro-inflammatory cytokines as indicated by the significantly higher IL-6/IL-10
and IL-8/IL-10 ratios observed in patients with and without ACLF as compared to
healthy subjects.
Another outstanding feature was the observation of clear differences in cytokine
profile of patients with ACLF according to the type of PE. Patients with active
alcoholism as PE exhibited very high IL-8 levels, as described previously (27,28).
Such increase in IL-8 was observed both in patients with and without AAH, although
the grade of increase was greater in the former group than in the second. Patients
with bacterial infection had a characteristic increase of a set of inflammatory
cytokines. Finally, patients with other or without PE had no differential increase in any
cytokine with respect to patients with active alcoholism or bacterial infection as PE.
These data suggest specific mechanisms for SI depending on the underlying trigger
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of ACLF. They also suggest that ACLF in patients with unidentifiable PE is unlikely
related to unrecognized bacterial infection. Finally, they support a cause-to-effect
relationship between PE, SI and ACLF development. This suggestion, however, does
not exclude other mechanisms. In fact, dysfunctional or damaged organs by itself
may stimulate cytokine and reactive oxygen species production (29) and, therefore,
contribute to the development and/or progression of ACLF.
It is important to note that increased plasma levels of G-CSF, GM-CSF, TNFα, IL-6 
and IFNγ have been shown to participate in the process called ‘emergency 
hematopoiesis’ which develops in the context of SI (30,31). Therefore, the activation
of these cytokines found in patients with ACLF probably contributes to the
leukocytosis associated with this syndrome and explain the close relationship
between WBC, ACLF severity and patient prognosis (1,3).
The mechanism by which SI induces ACLF was explored in the third part of the
analysis (Figures 1 and 2, Supplementary Figures 2, 3, 4 and 5 and logistic
regression and stepwise linear regression models). Renal failure, is a well-
recognized complication in patients with cirrhosis and bacterial infections (32), and
evidences have been presented suggesting that it may be related to a sequence of
events initiated by an exaggerated systemic inflammatory response that induces
aggravation of splanchnic arterial vasodilation and impairment in cardiac output,
homeostatic activation of endogenous neuro-hormonal systems to maintain arterial
pressure, renal vasoconstriction and vasoconstriction in other organs (i.e. liver and
brain), renal hypo-perfusion and renal failure (20,22). Our results showing that ACLF
develops in the setting of an accentuation in the SI and SCD already present in
patients with AD support that this sequence of events is also important in the
pathogenesis of the syndrome.
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However, several other findings obtained in the four analysis assessing the strength
of association of SI and SCD with ACLF strongly suggest that the mechanism of
ACLF is far more complex. 1. Whereas SI at enrolment (estimated by IL-6, IL-8 and
HNA2) was strongly related with the frequency and severity of ACLF, this was not
true for SCD (estimated by PRC); 2. The clinical course of ACLF was associated with
parallel changes in the plasma levels of SI markers but not with PRC. 3. PRC was
normal or slightly increased in many patients with ACLF or with ACLF-RF. In
contrast, IL-6 and IL-8 were markedly increased in almost all these patients. 4. The
logistic regression model assessing those markers (IL-8, IL-6, HNA2 and/or PRC)
independently associated with the presence of ACLF or ACLF-RF and the linear
regression model assessing the correlation of IL-8, IL-6, HNA2 and PRC with the
severity of ACLF and of ACLF-RF showed significant relationships with IL-6, IL-8 and
HNA2 but not with PRC. These results strongly suggest that non-hemodynamic
mechanisms mostly mediate the deleterious effects of SI in organ function and
participate in the pathogenesis of ACLF.
Three lines of evidence support this contention (33-38). The first includes
investigations showing that the extension of SI into the organs [(i.e. as a
consequence of extremely high circulating plasma levels of inflammatory mediators
and perhaps also of pro-inflammatory molecules (PAMPS and DAMPS)] may lead to
organ failure through direct deleterious effects on microcirculatory homeostasis,
mitochondrial function and cell survival. The second includes investigations in
patients and experimental animals with severe sepsis, a condition with many
similarities with ACLF, showing that renal failure may occur in the setting of hyper-
dynamic circulation and normal renal perfusion. Finally, the third derives from a
recent study on trans-jugular kidney biopsies in 65 cirrhotic patients awaiting liver
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transplantation. Among the numerous glomerular, vascular and acute or chronic
tubulo-interstitial lesions found in these patients, only cortical and medullary
infiltration by mononuclear cells and polymorphonuclear leukocytes associated with
tubular cell injury was independently associated with the presence of renal failure
(39). Therefore, as in severe sepsis, single or multi-organ failure in cirrhosis is
probably the result a complex process involving numerous mechanisms including
impairment is systemic circulatory and local microcirculatory functions,
microcirculatory thrombosis, mitochondrial and cell dysfunction and cell death.
A final important observation was that IL-8, IL-6 and HNA2 at enrolment and their
follow-up changes during hospitalization were directly associated with 28-day and 90-
day mortality (fourth part of the analysis, Figure 3, Supplementary Figure 6 and Table
5). Patients who died showed significantly higher baseline plasma levels of these
mediators than those who survived. Moreover, the plasma concentrations of IL-6, IL-
8 and HNA further increased during hospitalization in the former and decreased in
the latter group of patients. Sequential measurements of inflammatory mediators
could therefore be a sensitive tool to assess treatment effectiveness and to predict
prognosis in patients with ACLF.
In summary, the current study supports the SI hypothesis of AD and ACLF in
cirrhosis. 1. AD occurs in the setting of very high plasma levels of cytokines and
oxidized albumin; 2. ACLF develops when there is a further increase in these
inflammatory mediators; 3. Although ACLF frequently occurs in the setting of severe
SCD, inflammatory mediators are more strongly associated with the frequency,
severity and clinical course of ACLF than PRC, indicating that both hemodynamic
and non-hemodynamic mechanisms are important in the pathogenesis of ACLF.
Different profiles of cytokine response were observed. Whereas SI in AD was
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associated with very high levels of cytokines involved in both the innate and adaptive
immune systems, cytokines associated with ACLF were mainly cytokines involved in
the innate immune response. Different profiles of cytokine response were also
identified according to PEs of ACLF. Severity of SI at enrolment and progression or
regression of SI during hospitalization were closely associated with short-term
prognosis. Sequential measurement of inflammatory mediators may, therefore, be
useful as predictors of treatment effectiveness and patient prognosis.
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Figure Legends
Figure 1. Upper Panels (A and B). Scatter plots of individual patients classified by
the presence (red dots) or absence (green dots) of ACLF according to individual
values of plasma renin concentration (PRC) and interleukin-8 (IL-8) (left) or human
nonmercaptalbumin-2 (HNA2) (right). Two cut-off points for each marker divide each
cohort into 3 tertiles (T1: lower values; T2: intermediate values; T3: higher values).
Patients with ACLF are predominantly in the right part of the panels (higher degree of
SI). Lower Panels (C and D) show the presence of ACLF across the three tertiles of
both PRC and IL-8 and PRC and HNA2. Differences in the prevalence of ACLF
within tertiles (T2 versus T1 and T3 vs T2) were more significant with IL-8 and HNA2
than with PRC.
Figure 2. Scatter plots of individual values of plasma renin concentration (PRC),
interleukin-8 (IL-8), interleukin-6 (IL-6) and human nonmercaptalbumin-2 (HNA2) in
patients with ACLF (A) and with ACLF associated with renal failure (B). Horizontal
lines represent the upper normal limits (95% percentile of the distribution of values in
healthy subjects).
Figure 3. Upper Panels (A and B). Scatter plots of patients who died (red dots) or
survived (green dots) at 28-day after enrolment according to individual values of
plasma renin concentration (PRC) and interleukin-8 (IL-8) (left) or human
nonmercaptalbumin-2 (HNA2) (right). Two cut-off points for each marker divide each
cohort into 3 tertiles (T1: lower values; T2: intermediate values; T3: higher values).
Patients who died are predominantly in the right part of the panels (higher degree of
SI). Lower Panels (C and D) show the mortality rates observed within each tertile of
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both PRC and IL-8 and PRC and HNA2. Differences in mortality rates within tertiles
(T2 vs T1 and T3 vs T2) were statistically significant only with IL-8 and HNA2.
1Table 1. Plasma concentrations of renin (PRC), copeptin (PCC) and cytokines and albumin oxidation
fractions in healthy subjects and in patients with and without ACLF.
Healthy controls
N=40
No ACLF
N=285
ACLF
N=237 p-value*
Markers of SCD
PRC (micro IU/ml) 8(6-17) 65(17-242) 134(36-378) <0.001
PCC (pmol/L) 0(0-10) 9(3-23) 31(13-61) <0.0001
Pro-inflammatory Cytokines
TNF (pg/ml) 9(7-12) 20(14-27) 29(17-41) <0.001
IL-6 (pg/ml) 0.3(0.3-0.3) 21(11-41) 39(17-115) <0.001
IL-8 (pg/ml) 1.6(0.6-3.3) 37(20-76) 84(41-169) <0.001
MCP-1 (pg/ml) 337(218-413) 318(228-436) 410(288-713) <0.001
IP-10 (pg/ml) 328(234-428) 965(558-1676) 1184(665-2157) 0.004
MIP-1 (pg/ml) 13(6-17) 20(13-34) 28(19-50) <0.001
G-CSF (pg/ml) 2.1(1.8-11) 23(11-50) 32(14-83) 0.001
GM-CSF (pg/ml) 7.5(7.5-7.5) 4.7(2.0-9.5) 7.3(3.5-16.8) <0.001
Anti-inflammatory Cytokines
IL-10 (pg/ml) 1.1(0.4-1.1) 3.4(1.1-9.2) 8.1(2.1-29.9) <0.001
IL-1ra (pg/ml) 7(3-9) 10(5-22) 23(9-63) <0.001
Other Cytokines
IFN (pg/ml) 0.8(0.8-4.9) 6(2-18) 7(3-24) 0.044
IFNα2 (pg/ml) 3(3-3) 22 (8-56) 27 (11-63) 0.113 
Eotaxin (pg/ml) 94(55-122) 110(81-155) 124(89-179) 0.018
IL-17a (pg/ml) 0.7(0.7-2.7) 3.7(1.6-10.3) 4.5(1.6-15.6) 0.128
IL-7 (pg/ml) 1.4(0.1-3.9) 2.6(1.0-8.5) 3.5(1.6-11.1) 0.012
EGF (pg/ml) 17(4-29) 26 (9-66) 19(8-41) 0.046
VEGF (pg/ml) 26(26-28) 85 (28-226) 91(29-252) 0.745
Albumin Oxidation Fractions**
HMA (%) 71(68-74) 53(42-62) 45(33-56) <0.001
HNA1+HNA2 (%) 28(25-30) 46.4 (37.5-56.9) 51.8 (42.2-65.6) <0.001
HNA2 (%) 1.3(0.3-1.9) 4.5(2.5-8.8) 9.8(5.6-14.8) <0.001
Data are median (Inter-Quartille Range, IQR)
*P value between ACLF and NO ACLF.
** According to the redox state at cysteine 34
Table 2. Plasma concentrations of renin (PRC), copeptin (PCC) and cytokines and albumin oxidation
fractions according to the grade of ACLF.
ACLF – I
N=126
ACLF – II
N=86
ACLF – III
N=25
p-value*
Markers of SCD
PRC (micro IU/ml) 169(40-383) 114(28-352) 87(33-258) 0.771
PCC (pmol/L) 34(16.62) 27(13-45) 47(11.134) 0.224
Pro-inflammatory Cytokines
TNF(pg/ml) 30(21-43) 26(15-36) 32(17-43) 0.029
IL-6 (pg/ml) 34(18-96) 43(13-106) 111(32-355) 0.018
IL-8 (pg/ml) 62(37-112) 97(48-192) 144(80-292) <0.001
MCP-1 (pg/ml) 412(299-633) 376(277-646) 660(322-1773) 0.089
IP-10 (pg/ml) 1218(717-2258) 1162(617-1946) 1689(899-2728) 0.267
MIP-1 (pg/ml) 27(18-43) 28(19-55) 46(20-61) 0.112
G-CSF (pg/ml) 32(15-70) 29(14-81) 39(15-209) 0.673
GM-CSF (pg/ml) 6.8(3.7-15.0) 7.5(2.7-20.1) 11.3(5.1-29.6) 0.512
Anti-inflammatory Cytokines
IL-10 (pg/ml) 4.3(1.1-17.9) 15.3(5.5-41.5) 12.4(6.6-40.8) <0.001
IL-1ra (pg/ml) 17(10-45) 26(8-63) 49(24-135) 0.019
Other Cytokines
IFN (pg/ml) 7(3-24) 9(3-25) 7(2-16) 0.906
IFNα2 (pg/ml) 27(11-61) 25(12-74) 30(12-55) 0.968 
Eotaxin (pg/ml) 124(90-178) 128(90-180) 103(87-176) 0.951
IL-17a (pg/ml) 3.4(1.6-13.3) 5.5(1.8-27.8) 8.1(1.5-15.2) 0.623
IL-7 (pg/ml) 3.5(1.7-8.0) 3.8(1.4-14.6) 3.5(2.1-6.9) 0.790
EGF (pg/ml) 20(9-51) 19(7-38) 14(7-25) 0.233
VEGF (pg/ml) 95(28-246) 77(27-278) 89(35-201) 0.950
Albumin oxidation fractions&
HMA (%) 44(33-56) 45(32-58) 51(42-58) 0.621
HNA1+HNA2 (%) 52.9 (42.2-64.0) 51.3 (42.2-66.9) 48.7 (41.8-58.3) 0.781
HNA2 (%) 9.5(5.1-13.9) 9.8(5.6-15.1) 11.1(7.8-15.1) 0.205
Data are median (Inter-Quartille Range, IQR)
* Comparison between ACLF grades
& According to the redox state at cysteine 34
Table 3. Plasma concentrations of renin (PRC), copeptin (PCC) and cytokines and albumin oxidation
fractions in patients with ACLF according to the presence and type of Precipitating Events (PEs).
No PEs
(n=94)
Bacterial
infection-No
active
alcoholism
(n=63)
Active
alcoholism-No
bacterial
infection
(n=28)
Bacterial
infection-Active
alcoholism
(n=11)
Other Pes
(n=19) p-value*
Markers of SCD
PRC (micro IU/ml) 151 (50-474) 164 (28-447) 92 (31-295) 205 (112-998) 69 (25-210) 0.3021
PCC (pmol/L) 31 (15-59) 38 (16-64) 24 (7-36) 33 (4-112) 34 (16-55) 0.4654
Pro-inflammatory Cytokines
TNF (pg/ml) 29 (17-41) 32 (26-47) 21 (14-32) 34 (18-53) 27 (20-35) 0.0256
IL-6 (pg/ml) 30 (14-69) 72 (28-358) 37 (13-122) 83 (34-466) 34 (21-104) 0.0002
IL-8 (pg/ml) 64 (38-104) 92 (47-167) 211 (141-351) 158 (99-310) 50 (28-92) <0.0001
MCP-1 (pg/ml) 372 (279-484) 512 (299-1072) 515 (361-846) 832(294-1024) 342 (220-554) 0.0143
IP-10 (pg/ml) 1349 (717-2120) 1053 (631-2479) 882 (580-2265) 1596 (482-1996) 1153 (646-2215) 0.7356
MIP-1 (pg/ml) 24 (16-51) 30 (21-49) 28 (18-61) 43 (32-55) 26 (15-33) 0.2005
G-CSF (pg/ml) 29 (12-69) 39 (17-89) 32 (14-64) 35 (19-434) 31 (11-179) 0.4916
GM-CSF (pg/ml) 6.1 (3.2-14.4) 11.9 (3.3-32.5) 6.7 (4.2-14.4) 9.4 (3.8-17.4) 5.4 (2.6-12.5) 0.1754
Anti-inflammatory Cytokines
IL-10 (pg/ml) 6.2 (1.9-25.8) 17.8 (4.7-55) 8.3 (1.0-22.9) 24.5 (5.9-40.2) 5.1 (1.9-12.3) 0.0790
IL-1ra (pg/ml) 19 (8-47) 41 (13-100) 16 (8-49) 25 (14-37) 16 (9-33) 0.1666
Other Cytokines
IFN (pg/ml) 7 (2-27) 6 (3-16) 11 (3-24) 8 (4-17) 2 (1-28) 0.4394
IFNα2 (pg/ml) 23 (9-54) 41 (20-97) 19 (5-55) 30 (11-57) 17 (8-29) 0.0447 
Eotaxin (pg/ml) 122 (91-176) 130 (88-180) 131 (89-214) 91 (67-178) 93 (79-116) 0.0782
IL-17a (pg/ml) 3.7 (1.3-22.7) 4.4 (1.9-13) 2.9 (1.6-14.4) 8.1 (5.4-28.7) 2.8 (1.5-11.8) 0.5340
IL-7 (pg/ml) 3.0 (1.6-8.2) 5.8 (2.1-11.1) 2.7 (1.2-7.5) 6.4 (2.2-18.5) 2.2 (0.7-11.9) 0.0966
EGF (pg/ml) 17 (9-48) 20 (9-32) 14 (6-33) 20 (9-26) 16 (3-62) 0.9015
VEGF (pg/ml) 97 (34-286) 109 (28-240) 84 (27-127) 91 (56-148) 62 (14-299) 0.7647
Albumin Oxidation Fractions&
HMA (%) 44 (32-55) 44 (32-55) 49 (39-57) 32 (19-49) 48 (35-63) 0.2151
HNA1+HNA2 (%) 53.5 (42.6-65.7) 53.6 (41.8-66.7) 50.3 (42.8-59.6) 68.2 (50.6-80.9) 51.6 (37.4-64.7) 0.2489
HNA2 (%) 9.6 (5.1-14.8) 12.3 (8.0-15.3) 8.6 (7.0-13.3) 10.3 (6.5-14) 7.0 (3.9-10.7) 0.0682
Data are median (Inter-Quartile Range, IQR)
* p-value overall
& According to the redox state at cysteine 34
Table 4. Relationship between ACLF course, plasma concentrations of renin (PRC) and
inflammation markers.
Data are median (Inter-Quartille Range, IQR)
* Wilcoxon Signed Rank Sum Test.
** “Improvement”/ “Worsening”: reduction/ increase of ≥1 grade from enrolment in ACLF 
classification. “No change”: same classification as at enrolment in ACLF patients.
# Non-ACLF patients: patients without ACLF throughout the whole study
Parameter n Enrolment Last assessment p-value*
PRC (micro IU/ml)
Improvement ** 71 113.5 (27.5 – 294.3) 82.9 (23.3 – 330.4) 0.9187
No Change ** 26 93.1 (57.6 – 362.5) 262.3 (87.0 – 1212) 0.8450
Worsening ** 40 168.6 (81.7 – 1508.0) 259.7 (44.3 – 3023.0) 0.7415
Non-ACLF patients # 96 111.5 (29.0-284.1) 110.0 (59.5-251.4) 0.9188
IL-6 (pg/ml)
Improvement 71 32.2 (13.1 – 104.4) 25.5 (12.2 – 46.7) 0.0002
No Change 26 66.8 (25.2 –125.5) 50.1 (19.8 –117.7) 0.8589
Worsening 41 34.3 (17.7 – 111.2) 75.9 (20.6 – 134.3) 0.0744
Non-ACLF patients 87 25.0 (13.0-42.0) 16.5 (9.6-33.5) 0.0012
IL-8 (pg/ml)
Improvement 72 89.5 (36.7 – 174.3) 56.7 (35.6 – 119.1) 0.0003
No Change 26 118.8 (65.4 – 209.6) 186.8 (72.7 – 268.0) 0.8450
Worsening 41 82.7 (48.9 – 136.7) 116.0 (52.9 – 198.6) 0.1196
Non-ACLF patients 98 40.8 (22.7-75.4) 38.7 (22.4-68.7) 0.6137
HNA2 (%)
Improvement 72 9.6 (5.3 – 14.1) 8.9 (5.0 – 13.4) 0.2215
No Change 25 15.1 (11.0 – 20.3) 15.8 (11.2- 20.5) 0.6383
Worsening 41 10.7 (8.1 – 13.3) 13.2 (9.6 – 18.4) 0.0020
Non-ACLF patients 98 6.3 (3.3-9.4) 6.1 (2.1-11.7) 0.3099
Table 5. Changes from enrolment (median and inter-quartile range) in plasma concentrations of
renin (PRC) and inflammation markers according to mortality at 28 and 90 days after enrolment.
Data are median (Inter-Quartille Range, IQR)
(*) p<0.05 vs enrolment; (**) p<0.01 vs enrolment.
(#) p<0.05 vs change from baseline in survivors; (##) p<0.001 vs change from baseline in
survivors.
28-day Survivors 28-day Deaths
Marker N Enrolment Last
assessment
Change N Enrolment Last
assessment
Change
PRC
(micro
IU/ml)
138 116.7
(30.1-332.5)
119.8
(27.8-407)
-6.8
(-113.6-62.2)
37 99.0
(32.5-353.1)
201.9
(57.7-1156)
25.3
(-51.8-317.2)
IL-6
(pg/ml)
137 32.2
(15.0106.3)
26.3
(13.5-58.8)*
-5.3
(-36.9-10.5)
38 51.5
(21.2-173.1)
63.3
(31.4-168.9)
19.3
(-43.4-68.6) ##
IL-8
(pg/ml)
139 71.7
(35.6-153.7)
65.9
(36.0-125.0)*
-3.8
(-41.7-16.3)
38 107.8
(74.8-246.4)
147.3
(79.2-260.7)
6.7
(-42.1-62.2)
HNA2
(%)
139 9.5
(5.6-14.9)
10.7
(6.5-15.3)
-0.1
(-3.4-3.3)
36 12.9
(8.5-16.5)
14.1
(9.5-18.8) *
2.4
(-1.4-6.4) #
90-day Survivors 90-day Deaths
Marker N Enrolment Last
assessment
Change N Enrolment Last
assessment
Change
PRC
(micro
IU/ml)
105 108.7
(26.4-282.0)
89.6
(23.2-378.2)
-0.2
(-87.9-56.5)
66 171.3
(40.9-1576)
246.8
(64.1-1212)
19.7
(-171.2-204.8)
IL-6
(pg/ml)
104 40.3
(15.3-120.1)
23.6
(11.7-49.8) **
-8.4
(-57.4-3.0)
67 31.9
(17.3-117.8)
48.9
(25.5-129.2) *
14.7
(-12.2-60.9) ##
IL-8
(pg/ml)
106 83.2
(35.6-157.6)
56.4
(35.3-105.4) *
-7.2
(-50.7-9.2)
67 84.7
(50.5-204.6)
124.2
(64.8-227.1)
9.6
(-717.1-77.0) ##
HNA2
(%)
106 9.4
(5.6-13.6)
9.3
(5.3-15.0)
0.03
(-3.3-3.1)
65 12.5
(7.4-16.4)
13.4
(9.4-17.4) *
1.4
(-2.5-6.4)
*p<0.05 vs previous tertile; #p<0.01 vs previous tertile *p<0.05 vs previous tertile; #p<0.01 vs previous tertile
A B
C D
HNA2-T1 HNA2-T2 HNA2-T3 Overall PRC
PRC-T3 10/33 (30%) 31/60 (52%) 56/76 (74%) 97/169 (57%)
PRC-T2 16/51 (31%) 26/59 (44%) 34/58 (59%) 76/168 (45%)
PRC-T1 14/84 (17%) 17/46 (37%) 28/36 (78%) 59/166 (36%)
Overall
HNA2
40/168 (24%) 74/165 (45%)# 118/170 (69%)# n=503
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HNA2-T2
PRC.T3
HNA2-T3HNA2-T1
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IL-8-T3IL-8-T1
Figure 1
IL8-T1 IL8-T2 IL8-T3 Overall PRC
PRC-T3 17/53 (32%) 35/56 (62%) 47/64 (73%) 99/173 (57%)*
PRC-T2 14/47 (30%) 27/61 (44%) 34/60 (57%) 75/168 (45%)
PRC-T1 11/67 (16%) 20/53 (38%) 30/50 (60%) 61/170 (36%)
Overall
IL-8
42/167 (25%) 82/170 (48%)# 111/174 (64%)# n=511
Figure 2
A
B
m
ic
ro
IU
/m
l
pg
/m
l
pg
/m
l
m
ic
ro
IU
/m
l
pg
/m
l
pg
/m
l
IL8-T1 IL8-T2 IL8-T3 Overall PRC
PRC-T3 3/67 (5%) 5/53 (9%) 12/50 (24%) 20/170 (12%)
PRC-T2 2/47 (4%) 5/61 (8%) 12/60 (20%) 19/168 (11%)
PRC-T1 2/53 (4%) 10/56 (18%) 20/64 (31%) 32/173 (19%)
Overall
IL-8
7/167 (4%) 20/170 (12%)* 44/174 (25%)# N=511
HNA2-T1 HNA2-T2 HNA2-T3 Overall PRC
PRC-T3 3/84 (54%) 6/46 (13%) 10/36 (28%) 19/166 (11%)
PRC-T2 2/51 (4%) 7/59 (12%) 10/58 (17%) 19/168 (11%)
PRC-T1 3/33 (9%) 10/60 (17%) 18/76 (24%) 31/169 (18%)
Overall
HNA2
8/168 (5%) 23/165 (14%)# 38/170 (22%)* N=503
*p<0.05 vs previous tertile; #p<0.01 vs previous tertile *p<0.05 vs previous tertile; #p<0.01 vs previous tertile
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Figure 3
